Rebecca Gardner

TL;DR: It is found it is feasible to generate CAR products from each of the enrolled subjects, and the durability of remission is highly influenced by the functional persistence of CAR-T cells.

TL;DR: In this article, a multicentre initiative involving experts in paediatric cell therapy, supportive care and/or study of late effects from cancer and haematopoietic stem cell transplantation was convened to facilitate the comprehensive study of extended CAR-T cell-mediated toxicities and establish a framework for new systematic investigations of CAR T cell-related adverse events.

TL;DR: Given the poor outcomes for those with post-CAR relapse, study of relapse prevention strategies, such as consolidative hematopoietic stem cell transplant, is critical and warrants further investigation on prospective clinical trials.

TL;DR: This review describes constructs, clinical trial results, side effects, and future direction of CAR T‐cell therapy in B‐ALL.

TL;DR: Despite encouraging response rates and pharmacodynamics, the combination of decitabine and vorinostat on this intensive chemotherapy backbone was determined not feasible in B-ALL due to the high incidence of significant infectious toxicities.